Resources from the same session
988O - A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma
Presenter: Gustav Ullenhag
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
989O - Novel gene therapy in advanced solid malignancies: A phase I/II clinical trial
Presenter: Angelica Loskog
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Invited Discussant 988O and 989O
Presenter: Kevin Harrington
Session: Proffered paper session: Investigational immunotherapy
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: Investigational immunotherapy
Resources:
Webcast
990O - Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
Presenter: Ruth Perets
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
991O - First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors
Presenter: Rachel Sanborn
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
992O - Pembrolizumab for HPV-associated recurrent respiratory papillomatosis
Presenter: Sara Pai
Session: Proffered paper session: Investigational immunotherapy
Resources:
Abstract
Webcast
Q&A
Session: Proffered paper session: Investigational immunotherapy
Resources:
Webcast